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Abstract Although the adult brain contains neural stem cells
(NSCs) that generate new neurons throughout life, these
astrocyte-like populations are restricted to two discrete niches.
Despite their terminally differentiated phenotype, adult paren-
chymal astrocytes can re-acquire NSC-like characteristics fol-
lowing injury, and as such, these ‘reactive’ astrocytes offer an
alternative source of cells for central nervous system (CNS)
repair following injury or disease. At present, the mechanisms
that regulate the potential of different types of astrocytes are
poorly understood. We used in vitro and ex vivo astrocytes to
identify candidate pathways important for regulation of
astrocyte potential. Using in vitro neural progenitor cell
(NPC)-derived astrocytes, we found that exposure of more
lineage-restricted astrocytes to either tumor necrosis factor
alpha (TNF-α) (via nuclear factor-κB (NFκB)) or the bone
morphogenetic protein (BMP) inhibitor, noggin, led to re-
acquisition of NPC properties accompanied by transcriptomic
and epigenetic changes consistent with a more neurogenic,
NPC-like state. Comparative analyses of microarray data from
in vitro-derived and ex vivo postnatal parenchymal astrocytes
identified several common pathways and upstream regulators
associated with inflammation (including transforming growth
factor (TGF)-β1 and peroxisome proliferator-activated recep-
tor gamma (PPARγ)) and cell cycle control (including TP53)
as candidate regulators of astrocyte phenotype and potential.
We propose that inflammatory signalling may control the nor-
mal, progressive restriction in potential of differentiating as-
trocytes as well as under reactive conditions and represent
future targets for therapies to harness the latent neurogenic
capacity of parenchymal astrocytes.
Keywords Inflammation . Astrocytes . Neural stem cells .
Noggin . NFκB . Epigenetic
Introduction
Astrocytes were historically seen as support cells in the central
nervous system (CNS) and in fact discharge multiple func-
tions including regulation of energy metabolism, calcium sig-
nalling, synaptic transmission and mediating inflammatory
responses. This view has been expanded by the recognition
that astrocytes are also highly heterogeneous [1–3]. Interest-
ingly, neurogenic adult neural stem cells (aNSCs) that reside
in two niches (the subventricular zone (SVZ) of the lateral
ventricles and the subgranular zone (SGZ) of the dentate gyrus
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[4, 5]) have an astrocyte-like phenotype [6]. Even more in-
triguingly, there is a growing body of evidence that some
parenchymal astrocytes have a latent neurogenic capacity.
These observations underlie the need to identify regulatory
pathways that govern the ability of an astrocyte to express
NSC properties.
Early evidence for the neurogenic potential of parenchymal
astrocytes came from observations that immature astrocytes
from neonatal mouse adopt a radial glia-like phenotype when
cultured with embryonic day 14 (E14) cortical cells [7], whilst
astrocytes from embryonic or neonatal brain can form
multipotent neurospheres [8]. Furthermore, forced expression
of neurogenic transcription factors including Mash1, Ngn2 or
Dlx2 is capable of converting postnatal parenchymal astro-
cytes to functional neurons [9–12]. Collectively, these studies
show that immature parenchymal astrocytes have a latent neu-
rogenic potential that can be realised by manipulation of in-
trinsic transcriptional programmes or the cellular milieu. Im-
portantly, astrocytes from more mature brain after postnatal
day 10 (P10) are not capable of generating neurospheres, in-
dicating that the ability to dedifferentiate is a unique property
of immature astrocytes. Intriguingly, under inflammatory con-
ditions or following injury, mature parenchymal astrocytes
can become reactive and re-acquire more immature or neural
progenitor cell (NPC)-like properties [6, 13, 14]. Furthermore,
reactive astrocytes isolated from adult cortex can give rise to
multipotent neurospheres [15]. These observations underlie
the relevance of understanding the latent neurogenic capacity
of astrocytes for regenerative medicine strategies designed to
recruit astrocytes into repair of damaged brain. Reactive as-
trocytes are, by definition, present at the site of injury and
therefore offer an advantage over niche aNSCs that may reside
far from the injury site. Although these studies clearly dem-
onstrate the latent neurogenic capacity of some parenchymal
astrocytes, the signalling pathways and mechanisms that reg-
ulate the reprogramming of astrocytes to NPC-like states or
directly to neurons remain largely unknown [16].
The drive to identify genes for ‘stemness’ was initially led
by transcriptome studies [17, 18], but recently, the idea has
emerged that epigenetic signatures (including post-
translational modification to histones and DNA methylation)
can provide an indicator of cellular potential [19–24]. Indeed,
epigenetic reprogramming is key to the generation of induced
pluripotent stem cells (iPSCs). Whilst we are beginning to
unravel the role of epigenetics in NSCs and neuronal differ-
entiation, understanding of its contribution to maturation and
reactivation of astrocytes is poor.
Our aim was to explore the transcriptome and epigenetic
profile of different astrocyte populations to identify molecular
signatures of astrocyte plasticity. To do this, we used homo-
geneous populations of NPC-derived astrocytes that show a
differential ability to revert to an NPC-like state. We identified
two factors: the pro-inflammatory cytokine, tumor necrosis
factor alpha (TNF-α), known to play a role in reactive gliosis
and NPC proliferation [25–27] and the BMP antagonist, nog-
gin, as key regulators that govern reprogramming of astro-
cytes to NPCs. We also show that changes in epigenetic pro-
files accompany changes in cellular potential. Importantly, by
comparing in vitro and ex vivo astrocyte transcriptomes, we
provide evidence that there are likely to be common pathways
and regulators responsible for astrocyte identity and potential
in normal and injured brain that include pro- and anti-
inflammatory signalling. Further, we find that astrocyte poten-
tial is also reflected in their intrinsic epigenetic signatures.
These data add to a growing repository that aids identification
of regulatory pathways involved in maintenance or re-
acquisition of neurogenic NPC potential that may allow re-
cruitment of parenchymal astrocytes in repair strategies for
treatment of brain injury and degeneration.
Materials and Methods
Mice
All UK animal handling and procedures were performed ac-
cording to the UK Animals (Scientific Procedures) Act, 1986
under Home Office licence. All animal procedures in Luxem-
bourg were performed according to Federation of European
Laboratory Animal Science Associations (FELASA) guide-
lines for the use of animals in research. Transgenic mice were
genotyped using standard protocols and specific primers
(Table S1).
Cell Culture
Cell Line
The CTX12 cell line is a conditionally immortalised mouse
NPC line derived from E12-5 mouse cortex that has been
generated in-house at King’s College London by Dr. Bithell
and Dr. Williams. Cells were grown on poly-D-lysine (PDL)/
laminin-coated plastic (Sigma) in modified Sato’s medium
(modified Sato’s medium: Dulbecco’s modified Eagle’s medi-
um (DMEM)/F12 supplemented with 5.6 mg/ml glucose,
100 μg/ml bovine serum albumin (BSA), 16 μg/ml putres-
cine, 60 ng/ml progesterone, 400 ng/ml L-thyroxine,
300 ng/ml 3,3′,5-triiodothyronine, 5 μg/ml insulin, 5 μg/ml
apo-transferrin, 5 ng/ml sodium selenite, 1× glutamine, 1×
pen/strep) containing 10 ng/ml fibroblast growth factor 2
(FGF2), 20 ng/ml epidermal growth factor (EGF) and
100 nM 4-hydroxytamoxifen (4-OHT). Medium was changed
every 2–3 days and cells passaged using trypsin-EDTA and
trypsin inhibitor (Sigma). For astrocyte differentiation,
CTX12 cells were plated at 0.5×105 cells/cm2 and cultured in
modified Sato’s medium with 10 % foetal bovine serum (FBS)
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or 20 ng/ml bone morphogenetic protein 4 (BMP4) (Peprotech
and R&D Systems). Where indicated, cells were treated with
additional factors: noggin (500 ng/ml), TNF-α (50 ng/ml)
(Peprotech) and JSH-23 nuclear factor-κB (NFκB) Activation
Inhibitor II (JSH-23, 10 μM, Santa Cruz).
Primary Cells
Cortices were isolated from P21 Swiss Webster and collected
in calcium/magnesium-free Hank’s balanced salt solution
(HBSS), trypsinised and DNAseI treated (50 μg/ml, Sigma)
for 20 min at 37 °C and mechanically dissociated into a ho-
mogenous cell suspension [28]. Following washes and centri-
fugation, mixed glial cells were plated onto PDL (Sigma) in
DMEM/F12 (Invitrogen) with 100 U/ml penicillin/100 mg/ml
streptomycin (Sigma) and 10 % FBS (Biosera). Once conflu-
ent, cultures were shaken overnight at 180 rpm to remove
microglia and oligodendrocytes and treated for 4–7 days with
20 μM cytosine arabinoside (AraC) to kill remaining dividing
cells and obtain essentially pure astrocytes (>98 %), deter-
mined by immunofluorescence using anti-glial fibrillary acid-
ic protein (GFAP) (Millipore) and anti-S100β (Dako) for as-
trocytes, anti-Iba1 (Biocare, microglia), anti-O4 (Sigma, oli-
godendrocytes) and TuJ1 (Covance, neurons).
Preparation of Mouse Forebrain Cell Suspensions
and Fluorescence-Activated Cell Sorting (FACS)
of Astrocytes
Different developmental stages (P4, P10 or P21) of forebrains
from Aldh1l1-EGFP (Fthfd) transgenic mice (GenSat/
MMRRC) were collected in calcium/magnesium-free HBSS.
Tissue was diced and papain digested at 33 °C for 90 min
(20 U/ml, Sigma) in dissociation buffer [EBSS (Sigma), D(+
)-glucose 22.5 mM, NaHCO3 26 mM and DNaseI 125 U/ml
with EDTA 0.5 mM and L-cysteine–HCl 1 mM (Sigma)] and
washed 3× in dissociation buffer with BSA (1.0 mg/ml, Sig-
ma) and trypsin inhibitor (1.0 mg/ml, Sigma) before mechan-
ical dissociation through 5 ml and fire-polished Pasteur pi-
pettes to a single cell suspension. Cells were pelleted, resus-
pended in cold phosphate-buffered saline (PBS) with DNaseI
at 1×106 cell/ml, passed through a 70-μm filter and 7-
aminoactinomycin D (7-AAD, Sigma) added. FITC-posi-
tive/PE-Cy5-negative cells were sorted. FACS was performed
using a FACSAria I SORP running FACSDiva6.3 software
(BD Biosciences).
Immunocytochemistry
Cells were fixed for 10 min in 4 % paraformaldehyde,
permeabilised and incubated with primary antibodies in 1×
PBS with 10 % normal serum. Primary antibodies used were
anti-Olig2 (1:500; Millipore), anti-GFAP (1:400; Millipore),
anti-Ki67 (1:1,000; Abcam), anti-Nestin (1:1,000; Abcam),
anti-Sox2 (1:200; Santa Cruz), anti-O4 (Sigma, 1:200), anti-
Iba1 (1:200, Biocare), TuJ1 (1:1,000, Covance), anti-GFP
(1:2,000, Abcam), anti-bromodeoxyuridine (BrdU) (1:250,
Abcam) and anti-NFκB-p65 (1:500; Abcam). Primary anti-
bodies were visualised using specific AlexaFluor secondary
antibodies (Molecular Probes), and nuclei were counter-
stained with 4′,6-diamidino-2-phenylindole (DAPI). Cover-
slips were mounted in Prolong Gold anti-fade mounting me-
dium (Molecular Probes) and analysed using Zeiss
AxioImager Z1 microscopes and AxioVision software.
BrdU Labelling
Cells were pulsed with BrdU (100 μM, Sigma) for 24 h, fixed
with 4 % paraformaldehyde and treated with 2 N HCl for
45min and 0.1M borax (pH 8.5) for 15min before processing
for immunocytochemistry (above).
RNA Isolation, Microarray Hybridisation and Data
Analysis
Mouse Ref-8 Expression BeadChips (Illumina), washed and
scanned with Illumina BeadStation according to the Illumina
protocols. Raw data were analysed in R using BeadArray and
the Limma package. Ingenuity Pathway Analysis was used to
perform pathway analysis on geneset data (IPA, Ingenuity
Systems Inc. at www.ingenuity.com).
RNA Isolation and Reverse-Transcription PCR (RT-PCR)
Total RNAwas purified from cells using the Qiagen RNeasy
Mini Kit (Qiagen) as per manufacturer’s instructions. First
strand cDNA was synthesised from 1 to 2 μg of total RNA
using M-MLV reverse transcriptase (Promega). RT-PCR was
carried out on the Chromo4 System (Bio-Rad) using primers
listed in Table S1. PCR conditions were as follows: 3 min at
95 °C and 40 cycles of 10 s at 95 °C, 30 s at 60 °C and 30 s at
72 °C followed by 10-s 70–95° melt curves. All experiments
included three no-template controls and were performed on
three biological replicates with three technical replicates for
each sample and normalised to GAPDH. Results were
analysed using Opticon Monitor software (Bio-Rad), and rel-
ative gene expression levels were calculated using the Pfaffl
method [29].
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Cells were pelleted and lysed with TRIzol reagent
(Invitrogen). Total RNAwas further purified using an RNeasy
Mini Kit (Qiagen). Biological replicates were prepared for
microarrays using an Illumina TotalPrep RNA Amplification
Kit (Ambion) and amplified RNAs hybridised on Sentrix®
Chromatin Immunoprecipitation (ChIP) Analysis
ChIP was performed as described previously [30] and detailed
here briefly. Cells were crosslinked with 1 % formaldehyde in
PBS, quenched with 125 mM glycine and washed 3× with
cold PBS (containing protease inhibitors) before centrifuga-
tion and lysis in lysis buffer [5 mM PIPES pH 8.0, 85 mM
KCl, 0.5 % NP-40] for 30 min on ice. Pelleted nuclei were
resuspended in shearing buffer [50 mM Tris pH 8.1, 10 mM
EDTA, 0.1 % sodium dodecyl sulphate (SDS), 0.5 % sodium
deoxycholate] and sonicated in a Bioruptor (Diogenode) with
sufficient cycles (30 s on, 30 s off) to obtain an average chro-
matin shear size of 200–500 bp. Ten micrograms of pre-
cleared chromatin was immunoprecipitated in modified RIPA
buffer [140 mM NaCl, 10 mM Tris pH 7.5, 1 mM EDTA,
0.5 mM EGTA, 1 % TX-100, 0.01 % SDS, 0.1 % sodium
deoxycholate] with specific antibodies (2 μg), protease inhib-
itors and pre-blockedmagnetic protein G beads (ActiveMotif)
at 4 °C. Following washes [2×Wash Buffer 1–20mMTris pH
8.1, 50 mMNaCl, 2 mMEDTA, 1 % TX-100, 0.1 % SDS; 1×
Wash Buffer 2–10 mM Tris pH 8.1, 150 mM NaCl, 1 mM
EDTA, 1 % NP-40, 1 % sodium deoxycholate, 250 mM LiCl;
2× TE], the chromatin was eluted [0.1 M NaHCO3, 1 % SDS]
and de-crosslinked for 4 h at 65 °C with RNase and 200 mM
NaCl then treated with proteinase K for 2 h at 42 °C. ChIP
DNA was purified using a QIAquick PCR purification kit
(Qiagen, according to manufacturer’s instructions). ChIP-
qPCR was performed using ChIP DNA with promoter-
specific primers (see Table S1). Controls included non-
specific IgG and H3 ChIPs and ChIP-qPCR with primers for
non-specific regions of genomic DNA where enrichment is
not expected. Enrichment was analysed using a standard curve
to quantitate, and data were normalised to total H3 (unless
specified otherwise). qPCRs were run using an iCycler and
MyiQ software (Bio-Rad).
The antibodies used were as follows: anti-H3 (rabbit IgG,
AbCam), anti-H3K4me3 (rabbit IgG, AbCam; rabbit serum,
Active Motif) and anti-H3K27me3 (rabbit IgG, Upstate) with
rabbit IgG as a non-specific negative control. For primer se-
quences, see Table S1.
Results
Generation of Phenotypically Distinct Astrocytes
from NPCs
The mouse NPC line, CTX12, grown as a monolayer in the
presence of EGF, FGF2 and 4-OHT (collectively ‘GFs’) ex-
presses classic NPC markers including Nestin and Sox2
(Figs. 1a, b and S1A) and can differentiate into both neurons
and astrocytes (Fig. S1B, C). CTX12s cultured without GFs in
the presence of FBS or BMP4 for 3 days led to astrocyte
differentiation. In both conditions, CTX12 cells ceased prolif-
eration (loss of Ki67), down-regulated Nestin and Olig2 and
up-regulated GFAP (Fig. 1a, b). However, each condition gen-
erated homogeneous astrocytes with distinct morphology:
FBS astrocytes were flatter with few processes whilst BMP4
astrocytes were more ramified and stellate (Fig. 1a). To test
whether either population retained plasticity in an NPC-
permissive environment, FBS/BMP4 were removed and re-
placed by GFs for 3 days (‘dedifferentiation’ conditions).
FBS astrocytes became morphologically NPC-like, re-
entered cell cycle, down-regulated GFAP and up-regulated
Nestin and Olig2 (Fig. 1a, b). In contrast, few BMP4 astro-
cytes became proliferative, and morphology and gene expres-
sion were relatively unchanged (Fig. 1a, b). We subjected
dedifferentiated cells to a tripotential differentiation paradigm
[31] to test their ability to generate neurons and glia. Both
βIII-tubulin-positive neurons and GFAP-positive astrocytes
were readily obtainable from FBS astrocytes, but almost none
were generated from BMP4 astrocytes (Figs. 1c and S1D).
Thus, only FBS astrocytes re-acquire an NPC state following
dedifferentiation, suggesting that they differ in their neurogen-
ic potential from the BMP4 astrocytes.
Identification of a Common Set of Astrocyte-Regulated
Genes and Pathways
To identify pathways or factors that regulate astrocyte differ-
entiation and potential in our cellular model, we performed
microarray analysis on CTX12s, FBS and BMP4 astrocytes
(GEO accession number, with the authors). We identified
~8,000 probes with significantly changed expression upon
differentiation from NPCs to FBS or BMP4 astrocytes (6,326
and 6,256 genes, respectively, false discovery rate (FDR)<
0.05, Benjamini-Hochberg [32], Tables 1 and Table S2, qPCR
validation in Fig. S2). We first focussed on changes and
enriched pathways common to both astrocyte populations fol-
lowing differentiation. Classical astrocyte markers were highly
up-regulated including GFAP, Aqp4 and Slc39a12 [33]. Path-
way analysis (IPA, Ingenuity Systems, Inc.) following FBS or
BMP4 differentiation revealed a remarkable overlap in themost
significant results, including cell cycle and proliferation-
associated functions (Table S3), several of which are known
to be enriched in astrocytes [33]. IPA also permits prediction
of upstream regulators and their activation state, with several
common to BMP4 and FBS astrocytes (relative to CTX12)
including activation of TP53 and NFκB-related regulators and
inhibition of MYC (Table S3).
Identification of a Set of Differentially Regulated
Astrocyte Genes
Next, we focussed on genes differentially expressed between
BMP4 and FBS astrocytes and identified 1,775 probes (1,579
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genes, Fig. 2a and Table S4, FDR<0.05, Benjamini-
Hochberg) including genes known to be enriched in specific
astrocyte populations (Table S5) [33–35]. We first wanted to
identify candidates for maintenance of NSC/NPC and neuro-
genic properties in astrocytes. We compared differential gene
expression between BMP4 and FBS astrocytes with that of a
second, well-characterised NSC line, NS5 [36], and NS5-
derived FBS astrocytes (GEO accession number XXXX),
which have a similar phenotype to CTX12-derived FBS as-
trocytes (Fig. S3). We identified 372 ‘differentiation’ candi-
date genes (changed upon differentiation in BMP4 astrocytes
only) and 333 ‘plasticity’ candidate genes (changed in FBS
but not BMP4 differentiation, Fig. 2b and Table S6, FDR<
0.05). The most significant differentiation candidate was
Mmd2, recently shown to be important in astrogliogenesis
in vivo downstream of NFIA and Sox9 [37]. ‘Differentiation’
and ‘plasticity’ lists were used to infer over-represented sig-
nalling pathways (FDR<0.05) where we found 46 and 16
pathways, respectively (Fig. 2c and Table S6). ‘Differentia-
tion’ pathways included several linked with inflammation and
reactive astrocytes, including pro-inflammatory (interleukin
(IL)-1/6/8 and TNF-related) and anti-inflammatory (peroxi-
some proliferator-activated receptor (PPAR)) signalling
[38–42]. Upstream regulators included the NFκB complex,
Fig. 1 Molecular phenotype of CTX12 cells under proliferative
c o n d i t i o n s o r i n t h e p r e s e n c e o f FBS o r BMP4 . a
Immunocytochemistry showing GFAP (green) and Olig2 (red)
expression (top panels) and Nestin (green) and Ki67 (red) expression
(bottom panels). Nuclei are counterstained with DAPI (blue). CTX12s
were differentiated for 3 days (D3) with either FBS or BMP4 followed by
3 days of dedifferentiation (D6). bComparison ofMki67, Nes, GFAP and
Olig2 gene expression in conditions shown in a. c Example of a βIII-
tubulin-positive neuron (green) in FBS astrocyte cultures following
dedifferentiation and tripotential differentiation (top panel). Bottom
panel shows a representative image from BMP4 astrocytes under
similar conditions (GFAP in magenta and DAPI in blue).
Abbreviations: Astro, astrocyte; GF, growth factors (FGF2/EGF/4-
OHT). Error bars in b show SEMs, n=3
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which can be activated by upstream TNF signalling. In addi-
tion, inhibition of transforming growth factor (TGF)-β1 was
highly significant between BMP4 and FBS astrocytes. Inter-
estingly, BMP4 astrocytes had lower expression of the reac-
tive astrocyte marker, Serpina3n [40]. Despite few enriched
pathways in the ‘plasticity’ list, these too included inflamma-
tion as well as NFκB- and TNF-linked pathways such as
TWEAK and ILK signalling, the latter of which is activated
in reactive astrocytes [40] (Table S6). Thus, pathway analysis
results from in vitro astrocytes suggested that inflammatory
pathways might regulate NPC potential in astrocytes.
Activation of NFκB by TNF-α Leads to Dedifferentiation
of a Subset of BMP4 Astrocytes
Under inflammatory conditions or following injury, ma-
ture parenchymal astrocytes can become reactive and re-
acquire NPC-like properties [15]. Thus, we investigated
the effect of activating the NFκB pathway, a common
inflammatory signalling, on BMP4 astrocyte potential
using TNF-α. The NFκB p65 subunit was largely cyto-
plasmic in BMP4 astrocytes but became nuclear following
2 h with TNF-α in proliferative conditions, confirming
Table 1 Gene expression comparison between CTX12 and FBS/BMP4 astrocytes
Gene symbol FBS astrocytes BMP4 astrocytes Description
Rank Log2 fold change Rank Log2 fold change
Up
GFAPa, b 5 8.54 1 9.85 Glial fibrillary acidic protein
Aqp4b 6 8.53 2 8.64 Aquaporin 4
Clu 7 8.04 5 7.27 Clusterin
Socs3 33 5.23 34 4.92 Suppressor of cytokine signalling 3
Smad6 88 4.25 254 2.96 MAD homolog 6
Id2 151 3.75 112 3.75 Inhibitor of DNA binding 2
Pygb 191 3.39 99 3.89 Brain glycogen phosphorylase
Klf2 262 3.04 – – Krüppel-like factor 2
Nanog 835 1.88 731 1.9 Nanog homeobox
Vim 1,033 1.67 1,626 1.11 Vimentin
Stat1 1,229 1.50 1,070 1.54 Signal transducer and activator of transcription 1
Jak1 1,467 1.3 932 1.65 Janus kinase 1
Smad1 1,849 1.06 2,134 0.84 MAD homolog 1
Stat3 1,854 1.05 2,414 0.72 Signal transducer and activator of transcription 3
Sox2a, c 2,059 0.95 1,027 1.57 SRY-box-containing gene 2
Aldh1L1 2,174 0.88 1,126 1.49 Aldehyde dehydrogenase 1 family, member L1
S100β – – 464 2.33 S100 protein beta polypeptide
Down
Ccnb1c 4 −8.41 4 −8.27 Cyclin B1
Cdc20 14 −7.2 11 −7.3 Cell division cycle 20
Jag1 176 −3.75 253 −3.17 Jagged 1
Olig2a, b 183 −3.70 162 −3.79 Oligodendrocyte transcription factor 2
Sox8 238 −3.39 462 −2.22 SRY-box-containing gene 8
Hes5 374 −2.74 611 −1.92 Hairy and enhancer of split 5
Ccnd2 530 −2.27 444 −2.29 Cyclin D2
Pdgfra 1,816 −0.91 860 −1.57 Platelet-derived growth factor receptor alpha
Selected significantly up- and down-regulated genes identified by Illumina BeadChip array from over 6,000 significantly changed genes (FDR<0.05).
Rank denotes gene position in the up- or down-regulated gene lists ordered from highest to lowest fold change. Log2 change is the expression fold
change in FBS- or BMP4-derived astrocytes relative to CTX12 cells
ChIP chromatin immunoprecipitation
a Genes validated by immunofluorescence
bGenes validated by qPCR
cGenes validated by ChIP
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NFκB activation (Fig. S4A). BMP4 astrocytes in dediffer-
entiation conditions with TNF-α for 3 days showed a
significant increase in mKi67, nestin and Olig2 and de-
crease in GFAP expression compared to growth factor
(GF) alone and an increase in Ki67-positive cells
(Fig. 3a–c), many of which became morphologically more
NPC-like (Fig. 3a). A 24-h pulse of BrdU showed an
increase in BrdU-positive cells with TNF-α (Fig. S4B,
C). These effects were due to NFκB activation since they
were reversed by the specific NFκB inhibitor, JSH-23
[43] (Fig. 3a, c). Cultures were subsequently tested for
their neurogenic capacity, and a small number of ßIII-tu-
bulin-positive neurons were observed with TNF-α
(Fig. 3d). Therefore, NFκB activation through a TNF-α
treatment induces a subset of BMP4 astrocytes to re-enter
in the cell cycle and drives them to a more NPC-like state.
TNF-α-Treated BMP4Astrocytes Have aMore NPC-Like
Transcriptome
For a global view of TNF-α effects on BMP4 astrocytes,
we performed microarray analysis to compare BMP4 as-
trocytes (BMP) with those in dedifferentiation conditions
(GF) with or without TNF-α (TNF) (GEO accession num-
ber XXXX). We identified 3,712, 2,734 and 2,285 signif-
icantly changed genes comparing ‘TNF + GF v BMP4’,
‘TNF + GF v GF’ and ‘GF v BMP4’, respectively (FDR<
0.05, Benjamini-Hochberg, Table S7, qPCR validation in
Fig. S5). Interestingly, the most significant up-regulated
TNF gene, Lcn2, is a marker of reactive astrocytes in vivo
[40]. TNF-α regulated genes (compared to BMP4 or GF)
were enriched for cell cycle and growth and proliferation
functions with pathways including control of cell cycle,
Fig. 2 Candidate genes and
signalling pathways involved in
phenotype and potential of
specific astrocyte populations. a
Venn diagram showing number of
genes expressed at a significantly
different level between BMP4
and FBS astrocytes. b Venn
diagram showing genes whose
expressions were significantly
changed in FBS- or BMP4-
derived astrocytes compared to
undifferentiated CTX12 or NS5
cells (FDR<0.05). c Top
canonical pathways enriched in
the differentiation candidate gene
set ‘B’ and ‘plasticity’ candidate
gene set ‘A’ both shown in b
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p53, cancer-related pathways and TNF-related pathways
(Table S8), consistent with a change in proliferative po-
tential. Predicted upstream regulators included TNF and
NFκB, activation of MYC, WNT and other pro-
inflammatory molecules (including IFNG, IL1/17,
Table S8). One of the few predicted regulators in the
‘GF v BMP’ dataset was sonic hedgehog (SHH) (activat-
ed), also in the TNF-α dataset, which may reflect the
roles of pro-inflammatory molecules and SHH signalling
in astrocyte acquisition of NSC properties [44, 45]. Inter-
estingly, in dedifferentiation conditions (GF or TNF +
GF), Ascl1, encoding the proneural protein Mash1, was
up-regulated whilst members of Notch (Notch1, 4), Id
(Id1-3), Stat (Stat2) and Hes (Hes1, 5) families were
down-regulated, particularly in TNF + GF conditions.
This is consistent with a neurogenic NPC-like capability
since many are involved in the neurogenic–gliogenic
switch, including several regulated by BMP signalling
[46]. Taken together, these transcriptomic results highlight
that the expression levels of several NPC-associated
genes/pathways are more highly re-activated in the pres-
ence of TNF-α when compared to the corresponding
Fig. 3 A subset of BMP4 astrocytes treated with TNF-α re-enter the cell
cycle and re-acquire NPC characteristics. a Immunocytochemistry on
BMP4 astrocytes cultured in dedifferentiation conditions for 3 days
alone (GF), in the presence of TNF-α (+GF + TNFα) or with TNF-α
and JSH23 (+GF + TNFα + JSH23). JSH23 was added 30 min before
culturing astrocytes in dedifferentiation conditions in the presence of
TNF-α. Top row shows GFAP (green) and Olig2 (red), and bottom row
shows Nestin (green) and Ki67 (red). Nuclei were counterstained with
DAPI (blue). b Percentage of Ki67-positive cells in cultures shown in a. c
Gene expression levels of MKi67, Nestin (Nes), GFAP and Olig2 in
BMP4 astrocytes in conditions shown in (a, b). Data are expressed as
percentage of expression relative to D3 BMP4 astrocytes. d βIII-tubulin-
positive neurons (green) and GFAP-positive astrocytes (magenta) with
DAPI-labelled nuclei (blue) in BMP4 astrocyte cultures following
dedifferentiation with TNF-α followed by tripotential differentiation.
For b and c, n=3. Scale bars in a and d: 20 μm. P values in b and c:
*p<0.05, **p<0.01 (Student’s t test), error bars show SEMs
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BMP4-derived astrocytes under normal or dedifferentia-
tion conditions.
Mimicking CNS Damage Promotes NPC Properties
in BMP4-Derived Astrocytes
In keeping with down-regulation of BMP-regulated genes,
our analysis predicted inhibition of BMP itself under dediffer-
entiation conditions with and without TNF-α. This suggests
that BMP4 astrocytes produce endogenous BMPs and that
their inhibition is required for dedifferentiation. Interestingly,
reactive astrocytes adjacent to penetrating CNS injuries in
both spinal cord and brain up-regulate the BMP inhibitor,
noggin [47], and BMP secreted from blood endothelial cells
can induce reversible quiescence of NSC/NPCs in vitro, re-
versible with noggin [48]. We thus tested whether noggin
could induce re-acquisition of NPC properties in BMP4 astro-
cytes. This led to a change from astrocyte to NPC-like mor-
phology and a significant increase in proliferation (Fig. 4a, b),
concomitant with down-regulation of GFAP and up-
regulation of mKi67, Nestin and Olig2 (Fig. 4c) and down-
regulation of genes enriched in parenchymal astrocytes, in-
cluding Aqp4, Thrsp and Ngef (Table S5), to levels similar
to dedifferentiated FBS-derived astrocytes (Fig. S6). Noggin-
treated dedifferentiated astrocytes were also neurogenic, with
a small number of ßIII-tubulin-positive neurons (Fig. 4d).
Histone Modifications at Key Promoters Distinguish
Between Astrocyte Types
Differentiation, including acquisition and maintenance of a
more restricted fate, is known to be associated with epigenetic
changes [20, 21, 24, 49]. The ability of FBS astrocytes to
dedifferentiate compared to BMP4 astrocytes may reflect in-
trinsic epigenetic as well as transcriptional differences, includ-
ing histone modifications in promoters associated with active
(e.g. H3K9ac and H3K4me3) or repressed (H3K27me3) chro-
matin states [21, 50].
To look specifically at histone modifications associated
with cellular potential, we used ChIP-qPCR to examine rela-
tive levels of H3K4me3 and H3K27me3 at selected gene pro-
moters: Ccnb1 (positive cell cycle regulator), Nestin (NPC-
specific), Olig2 (neural-specific bHLH factor) and Sox2
(NSC/NPC marker). H3K4me3 was significantly decreased
at Ccnb1, Nestin and Sox2 in BMP4 astrocytes compared to
CTX12s and FBS astrocytes, whilst H3K27me3 increased at
Ccnb1, Nestin and Olig2 in both astrocytes, corresponding
with its down-regulation and cell cycle exit (Fig. 5a). Similar
Fig. 4 Inhibition of BMP signalling leads to re-acquisition of NPC
characteristics in BMP4 astrocytes. a Immunocytochemistry comparing
Ki67 (red) and GFAP (green) expression in BMP4 astrocytes in
dedifferentiation conditions with and without noggin (+GF + noggin
and +GF, respectively). Noggin was added simultaneously with GF.
Nuclei are counterstained with DAPI (blue). b Percentage of Ki67-
positive cells in the conditions shown in a. c Gene expression levels of
Mki67, Nes, GFAP and Olig2 in the conditions shown in a. Expression
levels are shown as percentage in +GF + noggin conditions relative to +
GF conditions (100 %). d βIII-tubulin-positive neurons (green) and
GFAP-positive astrocytes (magenta) with DAPI-labelled nuclei (blue)
in BMP4 astrocyte cultures following dedifferentiation with noggin
followed by tripotential differentiation. For b and c, n=3. Scale bars in
a and d, 20 μm. P values in b and c: *p<0.05, **p<0.01, ***p<0.001
(Student’s t test), error bars show SEMs
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trends are shown at the Ascl1 locus, where H3K4me3 was
significantly decreased in BMP4 astrocytes compared to
CTX12s and FBS astrocytes along with H3K27me3 increase
in both astrocytes (Fig. S7A, B). These data suggest that the
epigenetic landscape reflects the differentiation state and may
contribute to regulation of astrocyte plasticity. We therefore
analysed H3K4me3 at the same promoters in TNF-α and
noggin-treated BMP4 astrocytes in dedifferentiation condi-
tions. With TNF-α, Ccnb1, Nestin and Olig2 promoters
showed increased levels of H3K4me3, whilst noggin-
mediated dedifferentiation was accompanied by an increase
at all four loci (Fig. 5b), suggesting a more permissive
chromatin state. We next asked whether cultured primary as-
trocytes are associated with a less permissive chromatin state.
We cultured P21 mouse cortical astrocytes and compared rel-
ative H3K4me3 and H3K27me3 levels with our in vitro as-
trocytes. P21 astrocytes had significantly lower H3K4me3
enrichment at all four loci compared to FBS astrocytes and
Sox2 in BMP4 astrocytes and higher H3K27me3 at Sox2 and
Olig2 compared with both in vitro populations (Fig. 5c). Sim-
ilar results were obtained at the Ascl1 locus, where H3K4me3
was significantly decreased, whilst H3K27me3 was increased
in primary astrocytes compared to FBS- and BMP4-derived
astrocytes (Fig. S7C, D). Although cultured parenchymal
Fig. 5 Epigenetic comparison of phenotypically distinct astrocytes. a
H3K4me3 (left) and H3K27me3 (right) enrichment relative to total
H3 at specific gene promoters in CTX12 cells (grey), FBS astrocytes
(red) and BMP4 astrocytes (blue). Results are expressed as a percentage
of levels in CTX12 (100 %). b Left graph shows H3K4me3 enrichment
relative to total H3 at specific gene promoters in CTX12 cells (grey) and
BMP4 astrocytes after 3 days of dedifferentiation alone (+GF, yellow) or
with the addition of noggin (+GF + noggin, green). Results are expressed
as a percentage of levels in CTX12 (100%). The right-hand graph shows
a comparison between BMP4 astrocytes in dedifferentiation conditions
alone (+GF, yellow) and with TNF-α (+GF + TNFα). c Comparison of
H3K4me3 (left) and H3K27me3 (right) enrichment in FBS astrocytes
(red), BMP4 astrocytes (dark blue) and primary cortical astrocytes (light
blue). For a–c, n=3. *p<0.05, **p<0.01, ***p<0.001 (Student’s t test),
and error bars show SEMs
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astrocytes may represent a more immature/reactive phenotype
that non-cultured counterparts [33], our data are consistent
with the restricted state of later postnatal astrocytes and sug-
gest a more restricted state in BMP4 versus FBS astrocytes.
Thus, astrocyte plasticity and neurogenic potential are
reflected at the chromatin level.
Temporal Changes in the Postnatal Astrocyte
Transcriptome
To further identify regulatory pathways responsible for astro-
cyte plasticity associated with specific differentiation states,
we isolated ex vivo postnatal astrocytes by FACS from
Aldh1l1-EGFP mice (Fig. S8A–C) [33], and we performed
microarray analysis of astrocytes obtained from periods be-
fore, during and after which they lose neurosphere-forming
potential (GEO accession number XXXX) [8]. We identified
significantly changed genes (FDR<0.05, Benjamini-
Hochberg, qPCR validation in Fig. S9) from P4 to 10, P10
to 21 and P4 to 21 (Table S9) and determined functionally
enriched pathways and regulators (Table S10). Most changes
occurred from P4 to P10 (1,650 genes, Fig. 6a) with signifi-
cantly enriched cell cycle and neurological disorder functions
and cell cycle pathways and regulators (Fig. S10). Up-
Fig. 6 Developmental changes in gene expression in postnatal
astrocytes. a Clustered heatmap showing relative gene expression levels
in P4, P10 and P21 astrocytes from Aldh1l1-EGFP mice. Individual
biological replicates are shown as individual columns for P4 (n=3), P10
(n=4) and P21 (n=3). Relative expression levels are shown from low
(blue) to high (yellow). b Graphs show Gadd45, Foxm1, Ccnd1, Ntsr2,
TGF-β1, Gjb6, Mertk and PPARγ expression levels from FACSed
Aldh1l1-EGFP astrocyte populations. Expression levels are shown in
P10 (red) and P21 (blue) populations relative to P4 levels (x-axis). Data
are the average of three biological replicates. Error bars show SEMs. P
values: *p<0.05, **p<0.01, ns = not significant (Student’s t test). c Cell
cycle diagram. The scheme shows activated (green) or inhibited (red)
upstream regulators during in vivo astrocyte maturation as predicted by
IPA
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regulated genes also included Ntsr2, Gjb6 and Mertk
(Fig. 6b), all highly enriched in mature in vivo astrocytes
[33]. The top pathway identified was cell cycle regulation of
replication. Interestingly, this was enriched in TNF + GF gene
sets from BMP4 astrocytes, where many genes down-
regulated from P4 to P10 showed up-regulation with TNF-α
in vitro (Fig. S9). Signalling involving janus tyrosine kinase
(JAK) family kinases and IL-6 revealed down-regulation of
several genes by P10 that were significantly lower in BMP4
versus FBS astrocytes (Fig. S11). P10–P21 analysis (357
genes) again showed enrichment for cell cycle-associated
pathways (including GADD45) and P4–P21 analysis (2,732
genes) identified additional pathways, some of which were
identified in BMP4 astrocytes exposed to TNF-α
(Tables S10 and S9). These data suggest common pathways
in vitro and ex vivo that regulate astrocyte phenotype, poten-
tial and differentiation. We therefore interrogated upstream
regulators to identify regulators of astrocyte differentiation
and NSC potential.
P4–P10 upstream regulators included PPARG (and PPAR
GC1A), TP53 and CDKN2A activation and MYC, E2F1,
EP400 and vascular endothelial growth factor (VEGF) inhibi-
tion (Table S10) with additional regulators from P10-P21 in-
cluding FOXM1 (inhibition). Analysing P4–P21 also predict-
ed CDKN1A activation and TGF-β1 and CCND1 inhibition.
Broadly, these data support progressive cell cycle arrest
(Fig. 6c) accompanied by changes consistent with inhibition
of inflammatory signalling and identified other candidates
with potential roles during early postnatal stages.
Intriguingly, many candidates followed the same pattern of
inhibition/activation as BMP4 compared to FBS astrocytes or
the opposing activation status following TNF-α exposure
(Fig. 7 and Table S11). This further suggests that there are
common, upstream regulators that control astrocyte differen-
tiation as well as reactive phenotypes and dedifferentiation
events in our in vitro and ex vivo models.
Discussion
Adult neurogenesis occurs in two neurogenic niches from
aNSCs with astrocyte-like characteristics [5, 51, 52]. Identifi-
cation of glial progenitors outside these niches in healthy brain
[53, 54] and reactive astrocytes with progenitor-like charac-
teristics following injury [15] led to the notion that these cells
may represent a source of progenitors for repair. In fact, recent
studies have shown that stroke or excitotoxicity in mouse
elicit a latent neurogenic program in striatal astrocytes [55,
56]. However, our current understanding of the key genes,
pathways and mechanisms responsible for regulating astro-
cyte potential remains limited. Here, we describe two
in vitro NSC-derived astrocytes populations that differ in their
ability to dedifferentiate to an NPC-like state. We identified
pathways associated with response to CNS injury and inflam-
mation that regulate this differential potential and correlate
with findings from ex vivo postnatal astrocytes. We also pro-
vide evidence for other putative regulators of parenchymal
astrocyte development at postnatal stages when they acquire
a terminally differentiated status and which may be involved
in re-acquisition of NSC properties following injury. Finally,
our data add to existing datasets from astrocyte populations
that represent an invaluable resource to identify regulators of
phenotype and potential towards developing therapeutic strat-
egies for endogenous CNS repair.
Inflammatory Pathways Regulate Astrocyte Neurogenic
Potential and Differentiation
Continued expression of neurogenic fate determinants by cor-
tical astrocytes at early postnatal stages ensures a gradual
change from neurogenic to gliogenic RGCs and astrocytes
[57, 58]. Interestingly, these findings are supported by previ-
ous studies showing that early postnatal astrocytes can dedif-
ferentiate and give rise to neurogenic neurospheres, whilst this
Fig. 7 Candidate upstream
regulators in the astrocyte
neurogenic/non-neurogenic shift.
The scheme illustrates that
selected potential regulators that
are responsible for the shift of
neurogenic astrocytes (FBS-
derived and P4 astrocytes)
towards non-neurogenic
astrocytes (BMP4-derived and
P21 astrocytes) are also
responsible for the dedifferentia-
tion process under a
pro-inflammatory environment
(BMP4-derived astrocytes +
TNF-α)
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capacity declines during the second postnatal week [8]. Con-
ceptually, functional specialisation is likely to require cell cy-
cle exit and acquisition of a postmitotic status rendering astro-
cytes refractory to mitogens [59]. However, under inflamma-
tory conditions or following injury, mature parenchymal as-
trocytes can become reactive and re-acquire immature or
NPC-like properties [15, 60]. Nevertheless, signalling path-
ways that modulate astrogliosis with respect to time after in-
jury and the type of damage are complex and not fully known
[16, 61].
Here, we have used BMP4- and FBS-derived astrocytes to
identify regulators that control the balance between astrocyte
quiescence and maintenance of latent neurogenic potential.
We identified a likely role for pro-inflammatory signalling,
showing that NFκB activation by TNF-α can facilitate the
re-acquisition of NPC properties. Indeed, our results showing
that TNF-α treatment of BMP4-derived astrocytes modulates
several Notch members (such as a decrease in Notch1 expres-
sion levels), are in agreement with the recent discovery that
attenuated Notch1 signalling is necessary for neurogenesis by
striatal astrocytes [55]. Several other signalling molecules in-
cluding SHH and VEGF were also candidate regulators,
which is interesting in light of recent evidence for the likely
importance of signals from the vasculature for reactive astro-
cyte proliferation [62] and that SHH is necessary and suffi-
cient to induce NSC-like properties in astrocytes [45]. It is also
known that during brain injury, pro-inflammatory molecules,
such as IL-1 and TNF-α, are produced [63] and activate SHH
signalling and subsequent reactive gliosis in astrocytes [44]. It
is intriguing to speculate that our in vitro model may recapit-
ulate the action of a pro-inflammatory niche environment to
activate SHH and VEGF in BMP4 astrocytes, leading to re-
acquisition of NPC properties in a sub-population of cells.
This is supported by our ex vivo parenchymal astrocyte ex-
pression data before and after the ‘neurogenic’ period with
candidate upstream regulators including VEGF (inhibition).
SHH signalling was previously reported as a significantly
enriched pathway in postnatal astrocytes [33]. Our ex vivo
data are also consistent with the hypothesis that SHH, VEGF
and inflammatory-associated signalling may be involved in
control of NSC properties in parenchymal, non-niche astro-
cytes during normal development and reactive gliosis.
Other pro- and anti-inflammatory pathway candidates iden-
tified included TGF-β1 and PPAR signalling, respectively.
Based on our expression analyses, a more restricted (non-
neurogenic) astrocyte phenotype correlates with inhibition of
TGF-β1 and activation of PPAR (particularly PPARγ), and
both of these pathways are amongst those highly enriched in
postnatal astrocytes [33]. PPAR proteins (α, δ and γ) are
nuclear hormone receptors with roles including regulation of
inflammation in CNS disorders and following injury [39].
PPARα agonists can inhibit glial activation by lipopolysac-
charides (LPS) by inhibiting astrocyte (and microglial)
induction of TNF-α, IL-1β and IL-6, and PPARγ can inhibit
NFκB and JAK/STAT signalling [38, 39]. PPARγ agonists
can also affect the proliferation and differentiation of NSCs
[64] and thus appear to be bona fide candidates for further
investigation. TGF-β1 is a known mediator of inflammation
whose expression is increased in the CNS in association with
many disorders [42]. Exposure of postnatal parenchymal as-
trocytes to TGF-β1 in vitro causes widespread gene expres-
sion changes including up-regulation of the reactive astrocyte
marker Lcn2, enrichment of the PPARα/RXRα activation
pathway and association with immune or inflammation sig-
nalling (including NFκB and TNF) when used in combination
with LPS and IFNγ [42]. Together, these data lend weight to
the possibility of a cross-regulatory role between pro- and
anti-inflammatory regulators that may be common to normal
astrocyte differentiation (accompanied by loss of NSC prop-
erties) and re-acquisition of these properties following injury.
Moreover, we have shown the validity of our in vitro system
for identification of physiologically relevant candidate
pathways.
Changes in Cell Cycle Regulators Occur in the Postnatal
‘Neurogenic Window’
We identified few pathways or regulators linked with cell
cycle as differentially represented between our two in vitro
astrocytes; indeed, many were shared by both upon differen-
tiation. For example, both showed inhibition of FOXM1 and
activation of FOXO3—forkhead transcription factors with re-
ciprocally antagonist actions implicated in many cancers and
in cardiomyocyte proliferation [65, 66]. Furthermore, FOXO3
is also involved in regulation of NSCs, preventing premature
neuronal differentiation [67, 68]. FOXM1 was significantly
down-regulated during astrocyte maturation (from P4 to
P21). Despite the heterogeneity of in vivo astrocyte popula-
tions, our ex vivo array data revealed a significant role for cell
cycle-associated genes and regulators during maturation. This
was particularly evident during the P4–P10 transition, after
which the neurogenic capacity of parenchymal astrocytes is
lost [8]. This included down-regulation of genes that have
been previously shown to be decreased at P17 (Mcm2/5/6,
Tgif2 and Uhrf1 [33]). Our observation that Stat3 and Jak2
are down-regulated between P4 and P10 (and are lower in
BMP4 versus FBS astrocytes) implicate JAK kinases/IL-6
signalling in regulation of astrocyte plasticity. This is support-
ed by their up-regulation during induction of astrogliosis [69].
Endogenous BMP Signalling Is Able to Maintain In Vitro
Astrocyte Quiescence
Following CNS injury, reactive astrocytes can up-regulate
noggin expression [47]. Exogenous noggin in our in vitro
model increased proliferation and acquisition of a more
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NPC-like phenotype in BMP4 astrocytes, showing that en-
dogenous BMP signalling may regulate their proliferative
and neurogenic properties. Indeed, increased levels of secreted
BMPs upon loss of p21 in adult NSCs lead to their premature
differentiation into mature astrocytes [70]. However, expres-
sion of Bmp and noggin was not significantly different be-
tween BMP4 and FBS astrocytes (except Bmp1 is lower in
BMP4 astrocytes). Serum is often used as a proxy for BMPs;
however, different levels of BMPs can affect different cellular
responses. For example, low BMP2 levels increase prolifera-
tion of embryonic NPCs, whilst higher levels induce differen-
tiation [71]. Interestingly, this is due to the differential activa-
tion status of the BMP receptor BMPR1B (relative to
BMPR1A), which at higher levels leads to cell cycle arrest
(and apoptosis or terminal differentiation). Indeed, BMPR1A
and 1B have directly opposing roles (positive and negative,
respectively) in regulating astrogliosis in vivo [72]. BMP4
astrocytes express twofold higher Bmpr1b and significantly
lower Bmpr1a than FBS astrocytes, a process that is reversed
following dedifferentiation with TNF-α. Therefore, BMP4
and FBS astrocytes may have different responses to BMP
signalling, and future work is required to test whether this
explains noggin effects on astrocyte potential.
The Epigenetic Profile of Astrocytes Correlates with Their
Potential
The chromatin landscape acts as a cellular memory that deter-
mines and permits long-lasting transcriptional programmes
throughout development and differentiation [73]. Changes in
H3K4me3 and H3K27me3 are coordinately controlled at
genes activated or repressed, respectively, during differentia-
tion [74, 75]. We have demonstrated that FBS astrocytes have
more permissive chromatin at cell cycle- and NPC-related loci
when compared to BMP4 astrocytes, correlating with their
neurogenic potential. Moreover, TNF-α or noggin exposure
induces the dedifferentiation of a subset of BMP4 astrocytes,
and this is accompanied by epigenetic changes consistent with
increased cellular potential. Of note, the importance of epige-
netic regulation during neocortical development has been re-
cently investigated, showing that the polycomb group com-
plex (PcG) restricts neurogenic competence of NPCs and pro-
motes the transition of NPC fate from neurogenic to
astrogliogenic [76]. In this context, other studies in our group
have shown that NSC-derived astrocytes retain an active epi-
genetic signature at promoters of neural lineage-specific
genes, even though they are not expressed (unpublished data).
Our studies show that changes from neurogenic NPCs and
astrocytes to non-neurogenic astrocytes are reflected at the
transcriptional and epigenetic level. Further work will explore
the relative contribution of identified inflammatory pathways
and changes to the epigenome to astrocyte potential. Our data
also add to existing datasets from astrocyte populations that
represent an invaluable resource to identify regulators of phe-
notype and potential towards developing therapeutic strategies
for endogenous CNS repair.
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